RTW Venture Fund Name Change
News

RTW Venture Fund Name Change

Published
Topics

RTW Venture Fund, a London Stock Exchange-listed investment fund focused on identifying transformative assets with high growth potential across the life sciences sector is pleased to announce that the Company has changed its name to RTW Biotech Opportunities Ltd. The Guernsey registry has confirmed the name change, effective 22 June 2023.

Shareholdings will be unaffected by the change of name, and the Company's TDIMs, ISIN and SEDOLs all remain unchanged. Existing share certificates should be retained and will remain valid for all purposes.

Rod Wong, Managing Partner of RTW Investments, LP, the Company's Investment Manager commented:

"We are pleased to announce the change of the Company's name to RTW Biotech Opportunities Ltd which better places us among our listed healthcare and biotech investment company/trust peers and more accurately reflects the Company's full life cycle approach to biotech investing as a partner that can invest in both the private and public domains and across the capital structure."

For Further Information:

RTW Investments, LP
+44 (0)20 7959 6361
Woody Stileman, Managing Director
Krisha McCune, Director, Client Service

Buchanan
+44 (0)20 7466 5107
Charles Ryland
Henry Wilson
George Beale

Numis
+44 (0)20 7260 1000
Freddie Barnfield
Nathan Brown
Euan Brown

BofA Securities
+44 (0) 20 7628 1000
Edward Peel
Kieran Millar

Cadarn Capital
+44 (0) 73 6888 3211
David Harris

Elysium Fund Management Limited
+44 (0) 14 8181 0100
Joanna Duquemin Nicolle, Chief Executive Officer
Sadie Morrison, Managing Director

Morgan Stanley Fund Services USA LLC
+1 (914) 225 8885

About RTW Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW & RTWG) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.

RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Share article
Back to news

Related

Portfolio Company Update: Apogee Therapeutics IPO

Portfolio Company Update: Prometheus Biosciences

Portfolio company update: Third Harmonic Bio IPO

Portfolio company update: Third Harmonic Bio IPO

This website is not intended to offer or to promote the offer or sale of the shares (the “Shares”) of RTW Biotech Opportunities Ltd (the “Company”) in the United States or to any “U.S. persons” as defined in Regulation S (“US persons”) under the US Securities Act of 1933, as amended (the “Securities Act”). The materials contained herein are not for release, publication or distribution, directly or indirectly, in whole or in part, to any persons to whom or into or within any jurisdiction where to do so would constitute a violation of applicable law or regulation.

The information contained herein and on the pages that follow does not constitute or form a part of any offer to sell or issue, or the solicitation of any offer to purchase, subscribe for or otherwise acquire, any securities in the United States or in any jurisdiction in which, or to any person to whom, such an offer or solicitation would be unlawful.

The Company has not been and will not be registered under the US Investment Company Act of 1940, as amended (the “Investment Company Act”), and as such holders of the Shares are not and will not be entitled to the benefits of the Investment Company Act. The Shares have not been and will not be registered under the Securities Act, or with any securities regulatory authority of any state or other jurisdiction of the United States, and may not be offered, sold, resold, pledged, delivered, assigned or otherwise transferred, directly or indirectly, into or within the United States or to, or for the account or benefit of, any US Persons, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States and in a manner which would not result in the Company being required to register under the Investment Company Act. There has been and will be no public offer of the Shares in the United States. The offer and sale of the Shares have not been and will not be registered under the applicable securities laws of Australia, Canada, Japan or South Africa. Potential users of the information contained herein and on the pages that follow are requested to inform themselves about and to observe all applicable restrictions.

The information contained herein and on the pages that follow may contain forward-looking statements. Any statement other than a statement of historical fact is a forward-looking statement. Actual results may differ materially from those expressed or implied by any forward-looking statement. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. You should not place undue reliance on any forward-looking statement, which speaks only as of the date of its issuance. The Company may change these terms and conditions from time to time and any such changes will be posted on this website. Your access to this website is governed by the version of these terms and conditions then in force.

By clicking “Agree” below, you represent, warrant, undertake and agree that (1) you have read, understood and agree to be bound by the terms and conditions and other information set out herein, (2) you are permitted under applicable laws and regulations to receive the information contained herein and on the pages that follow, (3) you are either (a) located outside the United States and are not a US Person or (b) an existing shareholder of the Company who is a “qualified purchaser” as defined under the Investment Company Act and (4) you will not further transmit or send any information contained in this website to any other persons in the United States, to US Persons, or to any publications with a general circulation in the United States. If you cannot so represent, warrant, undertake and agree, you must click the button labelled “Decline” or otherwise exit this website.

You must accept preferences cookies and refresh your browser to view this video.

Alternatively, if cookies are being blocked by the browser, or you wish to view the video at its source, you can do so by visiting the link below: